Digoxin is a cardiac glycoside with a steroid-like structure used in order to treat cardiac arrhythmias and congestive heart failure [73], and rapamycin, a multitarget drug, is an inhibitor of mTOR complex 1 (mTORC1), which phosphorylates substrates including S6 kinase 1 (S6K1), eIF4E-binding protein 1 (4E-BP1), transcription factor EB (TFEB), unc-51-like autophagy-activating kinase 1 (Ulk1), and growth factor receptor-bound protein 10 (GRB-10). This evidence concerns the gene EIF4EBP1 and cardiac rhythm disease.